Top

Published in:

Open Access 01-12-2019 | Autism Spectrum Disorder | Research

Beneficial effects of xenon inhalation on behavioral changes in a valproic acid-induced model of autism in rats

Authors: A. P. Dobrovolsky, V. R. Gedzun, V. I. Bogin, D. Ma, T. E. Ichim, Iu. A. Sukhanova, A. V. Malyshev, V. A. Dubynin

Published in: Journal of Translational Medicine | Issue 1/2019

Abstract

Background

Xenon (Xe) is a noble gas that has been used for the last several decades as an anesthetic during surgery. Its antagonistic effect on glutamate subtype of NMDA (N-methyl-d-aspartate) receptors resulted in evaluation of this gas for treatment of CNS pathologies, including psychoemotional disorders. The aim of this study was to assess the behavioral effects of acute inhalation of subanesthetic concentrations of Xe and to study the outcomes of Xe exposure in valproic acid (VPA)-induced rodent model of autism.

Methods

We have conducted two series of experiments with a battery of behavioral tests aimed to evaluate locomotion, anxiety- and depression-like behavior, and social behavior in healthy, VPA-treated and Xe-exposed young rats.

Results

We have shown that in healthy animals Xe exposure resulted in acute and delayed decrease of exploratory motivation, partial decrease in risk-taking and depressive-like behavior as well as improved sensorimotor integration during the negative geotaxis test. Acute inhalations of Xe in VPA-exposed animals led to improvement in social behavior, decrease in exploratory motivation, and normalization of behavior in forced-swim test.

Conclusion

Behavioral modulatory effects of Xe are probably related to its generalized action on excitatory/inhibitory balance within the CNS. Our data suggest that subanesthetic short-term exposures to Xe have beneficial effect on several behavioral modalities and deserves further investigation.

DiCicco-Bloom E, Lord C, Zwaigenbaum L, Courchesne E, Dager SR, Schmitz C, et al. The developmental neurobiology of autism spectrum disorder. J Neurosci. 2006;26:6897–906. https://doi.org/10.1523/JNEUROSCI.1712-06.2006.CrossRefPubMedPubMedCentral

Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol. 2007;17:103–11. https://doi.org/10.1016/j.conb.2007.01.009.CrossRefPubMed

Ellegood J, Anagnostou E, Babineau BA, Crawley JN, Lin L, Genestine M, et al. Clustering autism: using neuroanatomical differences in 26 mouse models to gain insight into the heterogeneity. Mol Psychiatry. 2015;20:118–25.CrossRef

Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, et al. The epidemiology of autism spectrum disorders. Annu Rev Public Health. 2007;28:235–58. https://doi.org/10.1146/annurev.publhealth.28.021406.144007.CrossRefPubMed

Cattane N, Richetto J, Cattaneo A. Prenatal exposure to environmental insults and enhanced risk of developing Schizophrenia and Autism Spectrum Disorder: focus on biological pathways and epigenetic mechanisms. Neurosci Biobehav Rev. 2018. https://doi.org/10.1016/j.neubiorev.2018.07.001.CrossRefPubMed

Nelson SB, Valakh V. Excitatory/inhibitory balance and circuit homeostasis in autism spectrum disorders. Neuron. 2015;87:684–98. https://doi.org/10.1016/j.neuron.2015.07.033.CrossRefPubMedPubMedCentral

Lee EJ, Choi SY, Kim E. NMDA receptor dysfunction in autism spectrum disorders. Curr Opin Pharmacol. 2015;20:8–13. https://doi.org/10.1016/j.coph.2014.10.007.CrossRefPubMed

Rojas DC. The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment. J Neural Transm. 2014;121:891–905. https://doi.org/10.1007/s00702-014-1216-0.CrossRefPubMedPubMedCentral

Nicolini C, Fahnestock M. The valproic acid-induced rodent model of autism. Exp Neurol. 2018;299:217–27. https://doi.org/10.1016/j.expneurol.2017.04.017.CrossRefPubMed

10.

Bromley RL, Mawer GE, Briggs M, Cheyne C, Clayton-Smith J, García-Fiñana M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013;84:637–43. https://doi.org/10.1136/JNNP-2012-304270.CrossRefPubMedPubMedCentral

11.

Riikonen R. Treatment of autistic spectrum disorder with insulin-like growth factors. Eur J Paediatr Neurol. 2016;20:816–23. https://doi.org/10.1016/j.ejpn.2016.08.005.CrossRefPubMed

12.

Deb S, Farmah BK, Arshad E, Deb T, Roy M, Unwin GL. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder—a systematic review. Res Dev Disabil. 2014;35:711–25. https://doi.org/10.1016/j.ridd.2013.12.004.CrossRefPubMed

13.

White SW, Oswald D, Ollendick T, Scahill L. Anxiety in children and adolescents with autism spectrum disorders. Clin Psychol Rev. 2009;29:216–29. https://doi.org/10.1016/j.cpr.2009.01.003.CrossRefPubMedPubMedCentral

14.

Matson JL, editor. Handbook of assessment and diagnosis of autism spectrum disorder. Berlin: Springer; 2016. https://doi.org/10.1007/978-3-319-27171-2.CrossRef

15.

Nobusako S, Nishi Y, Nishi Y, Shuto T, Asano D, Osumi M, et al. Transcranial direct current stimulation of the temporoparietal junction and inferior frontal cortex improves imitation-inhibition and perspective-taking with no effect on the autism-spectrum quotient score. Front Behav Neurosci. 2017;11:84. https://doi.org/10.3389/fnbeh.2017.00084.CrossRefPubMedPubMedCentral

16.

Sanders RD, Franks NP, Maze M. Xenon: no stranger to anaesthesia. Br J Anaesth. 2003;91:709–17. https://doi.org/10.1093/bja/aeg232.CrossRefPubMed

17.

Azzopardi D, Robertson NJ, Bainbridge A, Cady E, Charles-Edwards G, Deierl A, et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. Lancet Neurol. 2016;15:145–53. https://doi.org/10.1016/S1474-4422(15)00347-6.CrossRefPubMedPubMedCentral

18.

Deng J, Lei C, Chen Y, Fang Z, Yang Q, Zhang H, et al. Neuroprotective gases—fantasy or reality for clinical use? Prog Neurobiol. 2014;115C:210–45. https://doi.org/10.1016/j.pneurobio.2014.01.001.CrossRef

19.

Coburn M, Sanders RD, Ma D, Fries M, Rex S, Magalon G, et al. Argon: the “lazy” noble gas with organoprotective properties. Eur J Anaesthesiol. 2012;29:549–51. https://doi.org/10.1097/EJA.0b013e328357bfdd.CrossRefPubMed

20.

Bessière B, Laboureyras E, Laulin JP, Simonnet G. Xenon prevents inflammation-induced delayed pain hypersensitivity in rats. NeuroReport. 2010;21:1167–71.CrossRef

21.

Vengeliene V, Bessiere B, Pype J, Spanagel R. The effects of xenon and nitrous oxide gases on alcohol relapse. Alcohol Clin Exp Res. 2014;38:557–63. https://doi.org/10.1111/acer.12264.CrossRefPubMed

22.

Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke. 2008;39:1307–13. https://doi.org/10.1161/01.STR.20.7.904.CrossRefPubMed

23.

Zhuang L, Yang T, Zhao H, Fidalgo AR, Vizcaychipi MP, Sanders RD, et al. The protective profile of argon, helium, and xenon in a model of neonatal asphyxia in rats. Crit Care Med. 2012;40:1724–30.CrossRef

24.

David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, et al. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J. 2007;22:1275–86. https://doi.org/10.1096/fj.07-9420com.CrossRefPubMed

25.

Meloni EG, Gillis TE, Manoukian J, Kaufman MJ. Xenon impairs reconsolidation of fear memories in a rat model of Post-Traumatic Stress Disorder (PTSD). PLoS ONE. 2014;9:e106189. https://doi.org/10.1371/journal.pone.0106189.CrossRefPubMedPubMedCentral

26.

Franks NP, Dickinson R, De Sousa SLM, Hall AC, Lieb WR. How does xenon produce anaesthesia? Nature. 1998;396:324. https://doi.org/10.1038/24525.CrossRefPubMed

27.

Suzuki T, Koyama H, Sugimoto M, Uchida I, Mashimo T. The diverse actions of volatile and gaseous anesthetics on human-cloned 5-hydroxytryptamine3receptors expressed in Xenopus oocytes. Anesthesiology. 2002;96:699–704. https://doi.org/10.1097/00000542-200203000-00028.CrossRefPubMed

28.

Yamakura T, Harris RA. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels: comparison with isoflurane and ethanol. Anesthesiology. 2000;93:1095–101. https://doi.org/10.1097/00000542-200010000-00034.CrossRefPubMed

29.

Weigt HU, Fohr KJ, Georgieff M, Georgieff EM, Senftleben U, Adolph O. Xenon blocks AMPA and NMDA receptor channels by different mechanisms. Acta Neurobiol Exp. 2009;69:429–40.

30.

Bantel C, Maze M, Trapp S. Neuronal preconditioning by inhalational anesthetics: evidence for the role of plasmalemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2009;110:986–95. https://doi.org/10.1097/ALN.0b013e31819dadc7.CrossRefPubMedPubMedCentral

31.

Mattusch C, Kratzer S, Buerge M, Kreuzer M, Engel T, Kopp C, et al. Impact of hyperpolarization-activated, cyclic nucleotide-gated cation channel Type 2 for the xenon-mediated anesthetic effect: evidence from in vitro and in vivo experiments. Anesthesiology. 2015;122:1047–59. https://doi.org/10.1097/ALN.0000000000000635.CrossRefPubMed

32.

Dobrovolsky A, Ichim TE, Ma D, Kesari S, Bogin V. Xenon in the treatment of panic disorder: an open label study. J Transl Med. 2017;15:137. https://doi.org/10.1186/s12967-017-1237-1.CrossRefPubMedPubMedCentral

33.

Ergaz Z, Weinstein-Fudim L, Ornoy A. Genetic and non-genetic animal models for autism spectrum disorders (ASD). Reprod Toxicol. 2016;64:116–40. https://doi.org/10.1016/j.reprotox.2016.04.024.CrossRefPubMed

34.

Malyshev AV, Abbasova KR, Averina OA, Solovieva LN, Gedzun VR, Gulyaev MV, et al. Fetal valproate syndrome as an experimental model of autism. Moscow Univ Biol Sci Bull. 2015;70:110–4. https://doi.org/10.3103/S0096392515030074.CrossRef

35.

Altman J, Sudarshan K. Postnatal development of locomotion in the laboratory rat. Anim Behav. 1975;23:896–920.CrossRef

36.

Sukhanova IA, Sebentsova EA, Khukhareva DD, Vysokikh MY, Bezuglov VV, Bobrov MY, et al. Early-life N-arachidonoyl-dopamine exposure increases antioxidant capacity of the brain tissues and reduces functional deficits after neonatal hypoxia in rats. Int J Dev Neurosci. 2019;78:7–18. https://doi.org/10.1016/j.ijdevneu.2019.06.007.CrossRefPubMed

37.

Sukhanova YA, Volodina MA, Sebentsova EA, Glazova NY, Manchenko DM, Inozemtseva LS, et al. Long-term changes in behavior and the content of BDNF in the rat brain caused by neonatal isolation: the effects of an analog of ACTH(4–10) Semax. Neurochem J. 2018;12:53–63. https://doi.org/10.1134/s1819712418010154.CrossRef

38.

Gill H, Thoresen M, Bishop S, Smit E, Liu X, Walloe L, et al. Equipotent subanesthetic concentrations of sevoflurane and xenon preventing cold-stimulated vocalization of neonatal rats. Anesthesiology. 2014;121:1194–202. https://doi.org/10.1097/ALN.0000000000000423.CrossRefPubMed

39.

Yang T, Zhuang L, Rei Fidalgoo AM, Petrides E, Terrando N, Wu X, et al. Xenon and sevoflurane provide analgesia during labor and fetal brain protection in a perinatal rat model of hypoxia-ischemia. PLoS ONE. 2012;7:e37020. https://doi.org/10.1371/journal.pone.0037020.CrossRefPubMedPubMedCentral

40.

Cattano D, Williamson P, Fukui K, Avidan M, Evers AS, Olney JW, et al. Potential of xenon to induce or to protect against neuroapoptosis in the developing mouse brain. Can J Anesth. 2008;55:429–36. https://doi.org/10.1007/BF03016309.CrossRefPubMed

41.

Baufreton J, Milekovic T, Li Q, McGuire S, Mouraud EM, Porras G, et al. Inhaling xenon ameliorates l-dopa-induced dyskinesia in experimental Parkinsonism. Mov Disord. 2018;00:1–11. https://doi.org/10.1002/mds.27404.CrossRef

42.

Dingley J, Hobbs C, Ferguson J, Stone J, Thoresen M. Xenon/hypothermia neuroprotection regimes in spontaneously breathing neonatal rats after hypoxic-ischemic insult: the respiratory and sedative effects. Anesth Analg. 2008;106:916–23.CrossRef

43.

Katz I, Murdock J, Palgen M, Pype J, Caillibotte G. Pharmacokinetic analysis of the chronic administration of the inert gases Xe and Ar using a physiological based model. Med Gas Res. 2015;5:8. https://doi.org/10.1186/s13618-015-0029-z.CrossRefPubMedPubMedCentral

44.

Gould TD. Mood and anxiety related phenotypes in mice: characterization using behavioral tests. New York: Humana Press; 2009.CrossRef

45.

Dickinson R, Peterson BK, Banks P, Simillis C, Martin JCS, Valenzuela CA, et al. Competitive inhibition at the glycine site of the N-methyl-d-aspartate receptor by the anesthetics xenon and isoflurane: evidence from molecular modeling and electrophysiology. Anesthesiology. 2007;107:756–67. https://doi.org/10.1097/01.anes.0000287061.77674.71.CrossRefPubMed

46.

Gruss M, Bushell TJ, Bright DP, Lieb WR, Mathie A, Franks NP. Two-pore-domain K+ channels are a novel target for the anesthetic gases xenon, nitrous oxide, and cyclopropane. Mol Pharmacol. 2004;65:443–52. https://doi.org/10.1124/mol.65.2.443.CrossRefPubMed

47.

Rinaldi T, Kulangara K, Antoniello K, Markram H. Elevated NMDA receptor levels and enhanced postsynaptic long-term potentiation induced by prenatal exposure to valproic acid. Proc Natl Acad Sci. 2007;104:13501–6. https://doi.org/10.1073/pnas.0704391104.CrossRefPubMed

48.

Rinaldi T, Perrodin C, Markram H. Hyper-connectivity and hyper-plasticity in the medial prefrontal cortex in the valproic acid animal model of autism. Front Neural Circuits. 2008;2:4. https://doi.org/10.3389/neuro.04.004.2008.CrossRefPubMedPubMedCentral

49.

Motz BA, Alberts JR. The validity and utility of geotaxis in young rodents. Neurotoxicol Teratol. 2005;27:529–33.CrossRef

50.

Fan L-W, Chen R-F, Mitchell HJ, Lin RCS, Simpson KL, Rhodes PG, et al. Alpha-phenyl-n-tert-butyl-nitrone attenuates lipopolysaccharide-induced brain injury and improves neurological reflexes and early sensorimotor behavioral performance in juvenile rats. J Neurosci Res. 2008;86:3536–47. https://doi.org/10.1002/jnr.21812.CrossRefPubMedPubMedCentral

51.

Schneider T, Przewłocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology. 2005;30:80–9. https://doi.org/10.1038/sj.npp.1300518.CrossRefPubMed

52.

Reynolds S, Millette A, Devine DP. Sensory and motor characterization in the postnatal valproate rat model of autism. Dev Neurosci. 2012;34:258–67. https://doi.org/10.1159/000336646.CrossRefPubMedPubMedCentral

53.

Pragnya B, Kameshwari JSL, Veeresh B. Ameliorating effect of piperine on behavioral abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice. Behav Brain Res. 2014;270:86–94. https://doi.org/10.1016/j.bbr.2014.04.045.CrossRefPubMed

54.

Wagner GC, Reuhl KR, Cheh M, McRae P, Halladay AK. A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate. J Autism Dev Disord. 2006;36:779–93.CrossRef

55.

Malyshev AV, Razumkina EV, Dubynin VA, Myasoedov NF. Semax corrects brain dysfunction caused by prenatal introduction of valproic acid. Dokl Biol Sci. 2013;450:126–9. https://doi.org/10.1134/S0012496613030046.CrossRefPubMed

56.

Bringas ME, Carvajal-Flores FN, López-Ramírez TA, Atzori M, Flores G. Rearrangement of the dendritic morphology in limbic regions and altered exploratory behavior in a rat model of autism spectrum disorder. Neuroscience. 2013;241:170–87.CrossRef

57.

Kim JW, Seung H, Kim KC, Gonzales ELT, Oh HA, Yang SM, et al. Agmatine rescues autistic behaviors in the valproic acid-induced animal model of autism. Neuropharmacology. 2017;113:71–81. https://doi.org/10.1016/j.neuropharm.2016.09.014.CrossRefPubMed

58.

Markram K, Rinaldi T, La Mendola D, Sandi C, Markram H. Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology. 2008;33:901–12. https://doi.org/10.1038/sj.npp.1301453.CrossRefPubMed

59.

Hanson E, Cerban BM, Slater CM, Caccamo LM, Bacic J, Chan E. Brief report: prevalence of attention deficit/hyperactivity disorder among individuals with an autism spectrum disorder. J Autism Dev Disord. 2013;43:1459–64. https://doi.org/10.1007/s10803-012-1677-7.CrossRefPubMed

60.

van Steensel FJA, Bögels SM, Perrin S. Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam Psychol Rev. 2011;14:302–17. https://doi.org/10.1007/s10567-011-0097-0.CrossRefPubMedPubMedCentral

61.

Servadio M, Melancia F, Manduca A, Di Masi A, Schiavi S, Cartocci V, et al. Targeting anandamide metabolism rescues core and associated autistic-like symptoms in rats prenatally exposed to valproic acid. Transl Psychiatry. 2016;6:e902. https://doi.org/10.1038/tp.2016.182.CrossRefPubMedPubMedCentral

62.

Wang CY, Cheng CW, Wang WH, Chen PS, Tzeng SF. Postnatal stress induced by injection with valproate leads to developing emotional disorders along with molecular and cellular changes in the hippocampus and amygdala. Mol Neurobiol. 2016;53:6774–85. https://doi.org/10.1007/s12035-015-9600-9.CrossRefPubMed

63.

Olde Loohuis NFM, Kole K, Glennon JC, Karel P, Van der Borg G, Van Gemert Y, et al. Elevated microRNA-181c and microRNA-30d levels in the enlarged amygdala of the valproic acid rat model of autism. Neurobiol Dis. 2015;80:42–53. https://doi.org/10.1016/j.nbd.2015.05.006.CrossRefPubMed

64.

Stryapko NV, Sazontova TG, Potievskaya VI, Khairullina AA, Vdovina IB, Kulikov AN, et al. Adaptation effect of repeated xenon application. Gen Reanimatol. 2014;10:50. https://doi.org/10.15360/1813-9779-2014-2-50-56.CrossRef

65.

Dufour-Rainfray D, Vourc’h P, Le Guisquet AM, Garreau L, Ternant D, Bodard S, et al. Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci Lett. 2010;470:55–9. https://doi.org/10.1016/j.neulet.2009.12.054.CrossRefPubMed

66.

Kataoka S, Takuma K, Hara Y, Maeda Y, Ago Y, Matsuda T. Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid. Int J Neuropsychopharmacol. 2013;16:91–103. https://doi.org/10.1017/S1461145711001714.CrossRefPubMed

67.

Hill RA, Kiss Von Soly S, Ratnayake U, Klug M, Binder MD, Hannan AJ, et al. Long-term effects of combined neonatal and adolescent stress on brain-derived neurotrophic factor and dopamine receptor expression in the rat forebrain. Biochim Biophys Acta Mol Basis Dis. 2014;1842:2126–35. https://doi.org/10.1016/j.bbadis.2014.08.009.CrossRef

68.

West AP. Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test. Prog Neuro-Psychopharmacol Biol Psychiatry. 1990;14:863-IN4.CrossRef

69.

Sukhanova IA, Sebentsova EA, Levitskaya NG. The acute and delayed effects of perinatal hypoxic brain damage in children and in model experiments with rodents. Neurochem J. 2016;10:258–72. https://doi.org/10.1134/S1819712416040127.CrossRef

Title: Beneficial effects of xenon inhalation on behavioral changes in a valproic acid-induced model of autism in rats
Authors: A. P. Dobrovolsky
V. R. Gedzun
V. I. Bogin
D. Ma
T. E. Ichim
Iu. A. Sukhanova
A. V. Malyshev
V. A. Dubynin
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Autism Spectrum Disorder
Valproate
Published in: Journal of Translational Medicine / Issue 1/2019
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-019-02161-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Beneficial effects of xenon inhalation on behavioral changes in a valproic acid-induced model of autism in rats

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

The French glioblastoma biobank (FGB): a national clinicobiological database

Preparing for cell culture scale-out: establishing parity of bioreactor- and flask-expanded mesenchymal stromal cell cultures

In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia

Journal of Translational Medicine advances in Translational Genomics and Genetics Era

Discriminatory ability of anthropometric measurements of central fat distribution for prediction of post-prandial hyperglycaemia in patients with normal fasting glucose: the DICAMANO Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page